JEERI NEOTECH INTERNATIONAL
JN-International Medical Corporation is a U.S. based biopharmaceutical corporation which since 1998 has been focused on developing vaccines and diagnostics for infectious disease for developing countries. This private corporation (formerly known as Jeeri Neotech International, Inc) was founded in 1998 by Dr. Jeeri R. Reddy with the help of Dr. Kelly F. Lechtenberg in a small rural town, Oakland, Nebraska. From there it grew and expanded until in the year 2000 the corporation moved to Omaha, Nebraska. JN-International Medical Corporation (JNIMC) has overseas business offices and clinical trial centers located in Abidjan, Ivory Coast in Africa and in Kuala Lumpur, Malaysia, with vaccine cold chain facilities in Burkina Faso and Singaporel.
JEERI NEOTECH INTERNATIONAL
Social Links:
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
1988-01-01
Address:
Omaha, Nebraska, United States
Country:
United States
Website Url:
http://www.jn-vaccines.org
Total Employee:
1+
Status:
Active
Contact:
402-884-3477
Email Addresses:
[email protected]
Total Funding:
12.41 M USD
Technology used in webpage:
SSL By Default DigiCert SSL AddThis Encryption Everywhere Shockwave Flash Embed Yahoo DNS Yahoo Yahoo! Business Email
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Founder
Official Site Inspections
http://www.jn-vaccines.org
- Host name: 104.21.87.157
- IP address: 104.21.87.157
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Jeeri Neotech International"
FDA, EMA and WHO guidance on updating COVID-19 vaccines for …
May 27, 2025 The World Health Organization (WHO) has also issued clear guidance on updating the antigen composition of COVID-19 vaccines for the 2025–2026 season. Their … See details»
18122023_JN.1_IRE_clean - World Health Organization (WHO)
Dec 19, 2023 Due to differential vaccine coverage and circulation of SARS-CoV-2 variants around the world, population immunity remains heterogenous globally and therefore, the … See details»
May 22 2025 Vaccines and Related Biological Products Advisory …
May 22, 2025 JN.1 Lineage Selection Facilitates Platform Diversity for Patient Choice and Timely Vaccine Access US COVID-19 Situation Current Surveillance See details»
Quick takes: WHO vaccine advisers say to stick with JN.1 ... - CIDRAP
The World Health Organization (WHO) today announced that its Technical Advisory Group on COVID-19 Vaccine Composition recently met to review the latest SARS-CoV-2 genetic … See details»
WHO Advisers Say Next Covid Vaccine Should Use Monovalent …
Apr 30, 2024 CIDRAP: WHO COVID Vaccine Advisers Recommend Switch To JN.1 Strain The World Health Organization (WHO) Technical Advisory Group on COVID-19 Vaccine … See details»
COVID-19: WHO designates JN.1 ‘variant of interest’ …
Dec 20, 2023 The UN World Health Organization (WHO) has said it is continuously monitoring the global spread of JN.1, a COVID-19 variant of interest, adding that current vaccines continue to offer protection against severe … See details»
ETF recommends updating COVID-19 vaccines to …
Apr 30, 2024 In making its recommendation, the ETF consulted the World Health Organization (WHO) , international partners and marketing authorisation holders for COVID-19 vaccines. The ETF also considered a wide range of … See details»
Covid-19: WHO adds JN.1 as new variant of interest - The BMJ
Dec 21, 2023 The World Health Organization has added a new covid-19 strain, JN.1, to its list of “variants of interest,” its second highest level of monitoring. Itself an offshoot of the omicron … See details»
The JN.1 variant of COVID-19: immune evasion, …
Through the synthesis of recent insights into JN.1’s epidemiology, vaccine response, and antiviral efficacy, this review aims to deepen understanding of the COVID-19 variant landscape and inform targeted surveillance and proactive … See details»
WHO COVID vaccine advisers recommend switch to …
Apr 29, 2024 The World Health Organization (WHO) Technical Advisory Group on COVID-19 Vaccine Composition, which meets about every 6 months to assess if any changes are needed, has recommended that the next COVID vaccine … See details»
Statement on the antigen composition of COVID-19 …
Apr 26, 2024 As virus evolution is expected to continue from JN.1, future formulations of COVID-19 vaccines should aim to induce enhanced neutralizing antibody responses to JN.1 and its descendent lineages. One approach … See details»
FDA vaccine advisers recommend sticking with JN.1 strain for
May 22, 2025 The Food and Drug Administration (FDA) vaccine advisory group today recommended sticking with a monovalent JN.1 lineage vaccine for COVID vaccines for the … See details»
15042024_JN.1_URE_clean - World Health Organization (WHO)
Apr 15, 2024 Executive Summary JN.1 is currently the most prevalent SARS-CoV-2 variant globally. Considering the available evidence, the additional public health risk posed by JN.1 is … See details»
The rising SARS‐CoV‐2 JN.1 variant: evolution, infectivity, immune ...
Jul 29, 2024 This review thoroughly evaluates the JN.1 variant's impact on public health and its implications for future vaccine and therapeutic development, contributing to ongoing efforts to … See details»
mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross …
Apr 30, 2025 These data suggest these strains are antigenically similar with relatively few spike differences between JN.1 and KP.2/JN.1-related subvariants. Our results demonstrate the … See details»
FDA advisers recommend COVID-19 vaccine targeting JN.1
May 23, 2025 The Vaccines and Related Biological Products Advisory Committee made the same recommendation in summer 2024, suggesting COVID-19 vaccine makers focus on the … See details»
The JN.1 variant of COVID-19: immune evasion, transmissibility, …
Jan 30, 2025 The emergence of the COVID-19 JN.1 variant has raised global health concerns as it gains prevalence in several regions worldwide. First identified in August 2023, JN.1 … See details»
Novavax Prepared to Deliver Protein-based Non-mRNA JN.1 …
Apr 26, 2024 Today the World Health Organization’s (WHO) Technical Advisory Group on COVID-19 Vaccine Composition recommended the use of a monovalent JN.1 lineage COVID … See details»
Vaccines and Related Biological Products Advisory Committee …
On June 5, 2024, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet in open session to discuss and make recommendations on the selection of the 2024 … See details»
02022024_JN.1_URE_clean - World Health Organization (WHO)
Jan 9, 2023 Executive Summary JN.1 is the most prevalent SARS-CoV-2 variant globally. Considering the available evidence, the additional public health risk posed by JN.1 is still … See details»